Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France
The 4CMenB, a protein-based vaccine, was licensed in Europe in 2013 against invasive meningococcal disease caused by serogroup B and is currently implemented in several countries although according to different national strategies. Isolate coverage estimation is required as vaccine-targeted antigens...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Taylor & Francis Group
2021-12-01
|
| Rangatū: | Human Vaccines & Immunotherapeutics |
| Ngā marau: | |
| Urunga tuihono: | http://dx.doi.org/10.1080/21645515.2021.2004055 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|